Long-term use of dipeptyl peptidase-4 inhibitors suppresses systemic oxidative stress in rats with type 2 diabetes
https://doi.org/10.47093/22187332.2019.4.21-30
摘要
Induction of oxidative stress is one of the main mechanisms responsible for the development of micro- and macrovascular angiopathy in patients with type 2 diabetes mellitus (DM-2).
Aim. To evaluate the influence of long-term treatment with inhibitors of dipeptidyl peptidase-4 (DPP-4) on the characteristics of oxidative stress and the state of antioxidant defense system in rats with induced DM 2.
Materials and methods. We divided 60 Wistar albino rats into 5 groups: group 1 (control) – normal animals; groups 2–5 rats with DM 2, induced by streptozotocin: group 2 – without treatment with DPP 4; group 3 – rats, treated with saxagliptin (0.45 mg/kg); group 4 – rats, treated with sitagliptin for 3 weeks (0.6 mg/kg); group 5 – rats, treated with vildagliptin (9 mg/kg). At the end of the experimental phase we determined the level of superoxide anion radical (O2-), hydrogen peroxide (H2O2), nitrite (NO2-), reduced glutathione, as well as the activity of catalase and superoxide dismutase (SOD) in the blood of rats using a diode array spectrophotometer.
Results. Induction of DM-2 in experimental animals led to a significant increase of reactive oxygen species (ROS): superoxide radical and hydrogen peroxide and to decrease in NO2-, reduced glutathione, catalase and SOD activity. Comparing groups 3–5 with group 2, treatment with DPP-4 inhibitors reduced excessive generation of superoxide radical (O2-) and hydrogen peroxide (H2O2) (especially significant in the group with vildagliptin) and increased the activity of catalase and superoxide dismutase (especially significant in the group with v sitagliptin) but the normal values, received in group 1, were not reached. Treatment with all DPP-4 inhibitors brought the level of nitrite (NO2-) up to normal, comparable with group 1.
Conclusions. DPP-4 inhibitors suppress systemic oxidative stress in rats with induced DM 2 via reduction of prooxidative molecules production and activation of antioxidant defensive system.
关于作者
S. Bolevich
Sechenov First Moscow State Medical University (Sechenov University)
俄罗斯联邦
俄罗斯联邦
P. Litvitsky
Sechenov First Moscow State Medical University (Sechenov University)
俄罗斯联邦
俄罗斯联邦
V. Jakovljevic
University of Kragujevac
S. Bolevich
Sechenov First Moscow State Medical University (Sechenov University)
俄罗斯联邦
俄罗斯联邦
参考
1. Дедов И.И. Сахарный диабет типа 2: от теории к практике. Москва: МИА, 2016; 576c. ISBN 978-5-9986-0248-1.
2. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017; 20 (1): 13–41.
3. Filippas-Ntekouan S, Filippatos TD, Elisaf MS. SGLT2 inhibitors: are they safe? Postgrad Med. 2018; 130 (1): 72-82. DOI: 10.1080/00325481.2018.1394152. PMID: 29039237.
4. Дедов И.И., Шестакова М.В. Осложнения сахарного диабета. Лечение и профилактика. Москва: МИА, 2017; 744 с. ISBN 978-5-9986-0300-6.
5. Румянцева С.А., Силина Е.В., Орлова А.С. и др. Гипергликемия и свободнорадикальный дисбаланс как прогностические маркеры острого нарушения мозгового кровообращения. Анналы клинической и экспериментальной неврологии. 2012; 6 (4): 26-9.
6. Sani NF, Belani LK, Sin CP et al. Effect of the combination of gelam honey and ginger on oxidative stress and metabolic profile in streptozotocin-induced diabetic Sprague-Dawley rats. Biomed Res Int. 2014: 160695. DOI: 10.1155/2014/160695. PMID: 24822178.
7. Gupta V, Kalra S. Choosing a gliptin. Indian J Endocrinol Metab. 2011; 15: 298–308. DOI: 10.4103/2230-8210.85583. PMID: 22029001
8. Tatosian DA, Guo Y, Schaeffer AK, et al. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Ther. 2013 Dec; 4 (2): 431-42. DOI: 10.1007/s13300-013-0045-8. PMID: 24163113
9. Jakovljevic V, Milic P, Bradic J, et al. Standardized Aronia melanocarpa Extract as Novel Supplement against Metabolic Syndrome: A Rat Model. Int J Mol Sci. 2018 Dec 20; 20 (1): 6. DOI: 10.3390/ijms20010006. PMID: 30577476.
10. Hulman A., Vistisen D., Glümer C. et al. Glucose patterns during an oral glucose tolerance test and associations with future diabetes, cardiovascular disease and all-cause mortality rate. Diabetologia. 2018. Vol. 61 (1): 101–7. DOI: 10.1007/s00125-017-4468-z. PMID: 28983719.
11. Zheng Y., Ley S., Hu F. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology. 2018. Vol. 14 (2): 88–98. DOI: 10.1038/nrendo.2017.151. PMID: 29219149.
12. Rehman K, Akash MSH. Mechanism of Generation of Oxidative Stress and Pathophysiology of Type 2 Diabetes Mellitus How Are They Interlinked? J Cell Biochem. 2017; 118 (11) :3577-85. DOI:10.1002/jcb.26097
13. Breitzig M, Bhimineni C, Lockey R, Kolliputi N. 4-Hydroxy-2-nonenal: a critical target in oxidative stress? Am J Physiol Cell Physiol. 2016 Oct 1; 311 (4): C537-C543. DOI: 10.1152/ajpcell.00101.2016
14. Nowotny K, Jung T, Höhn A, et al. Advanced glycation end productsand oxidative stress in type 2 diabetes mellitus, Biomolecules. 2015; 5 (1): 194-222. DOI: 10.3390/biom5010194.
15. Pеrez-Matute P, Zulet MA, Martínez JA. Reactive species and diabetes: counteracting oxidative stress to improve health. Curr Opin Pharmacol. 2009; 9 (6): 771-9. DOI: 10.1016/j.coph.2009.08.005.
16. Murakami K, Kondo T, Ohtsuka Y. et al. Impairment of glutathione metabolism in erythrocytes from patients with diabetes mellitus. Metabolism. 1989; 38 (8): 753-8. DOI: 10.1016/0026-0495(89)90061-9. PMID: 2569661
17. Kottenberg E, Thielmann M, Kleinbongard P, et al. Myocardial protection by remote ischaemic pre-conditioning is abolished in sulphonylurea-treated diabetics undergoing coronary revascularisation. ActaAnaesthesiol Scand. 2014; 58 (4): 453-62. DOI: 10.1111/aas.12278. PMID: 24548338.
18. Tatosian DA, Guo Y, Schaeffer AK, et al. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Therapy. 2013; 4 (2): 431-42. DOI:10.1007/s13300-013-0045-8
19. Sherif IO, Al-Shaalan NH. Vildagliptin Attenuates Hepatic Ischemia/Reperfusion Injury via the TLR4/NF-κB Signaling Pathway. Oxid Med Cell Longev. 2018: 3509091. DOI:10.1155/2018/3509091. PMID: 30405876.
20. El-Kashef DH, Serrya MS. Sitagliptin ameliorates thioacetamide-induced acuteliver injury via modulating TLR4/NF-KB signaling pathway in mice. Life Sci. 2019; 228: 266-273. DOI:10.1016/j.lfs.2019.05.019.
21. Sangle G., Patil M., Deshmukh N. et al. Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. European journal of clinical pharmacology. 2018. Vol. 74 (5): 561–569. DOI: 10.1007/s00228-018-2433-5.
22. Trocha M, Krzystek-Korpacka M, Merwid-Ląd A, et al. Sitagliptin-Dependent Differences in the Intensity of Oxidative Stress in Rat Livers Subjected to Ischemia and Reperfusion. Oxid Med Cell Longev. 2019 Oct 31: 2738605. DOI:2019:2738605. PMID: 31781329
23. Refaat R, Sakr A, Salama M, El Sarha A. Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats. Drug Dev Res. 2016; 77 (6): 300-9. DOI:10.1002/ddr.21324.
24. Helal MG, Zaki MMAF, Said E. Nephroprotective effect of saxagliptin againstgentamicin-induced nephrotoxicity, emphasis on anti-oxidant, anti-inflammatoryand anti-apoptic effects. Life Sci. 2018; 208 : 64-71. DOI:10.1016/j.lfs.2018.07.021.
评论
浏览:
876
Email this article 